Lucid Diagnostics, Inc. (LUCD)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.94-1.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · LUCD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on building commercial momentum by converting EsoGuard test demand into recognized revenue while awaiting Medicare coverage.
Stated as a priority in 2 of last 2 quarters. EsoGuard revenue increased from $1.3 million in 2026-Q1 to $1.5 million in 2026-Q2, reflecting commercial momentum. However, test volume declined from 3,177 to 2,770 tests, indicating mixed delivery on converting demand to revenue.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Lucid’s commercial momentum strengthened... positioning Lucid to capitalize on EsoGuard’s clinical and commercial opportunity.”
“We continue to build commercial momentum for EsoGuard by generating consistent demand... to convert EsoGuard demand to revenue.”
Deploy net proceeds from the $18 million common stock offering to support working capital and general corporate purposes.
Stated in 2 of last 2 quarters. The company raised approximately $18 million in April 2026 and reported $45 million proforma cash at 2026-Q1 end, which declined to $33.4 million by 2026-Q2. The trajectory shows use of proceeds for working capital consistent with stated priority.
“Lucid had cash and cash equivalents of $33.4 million as of June 30, 2026.”
“Ended 1Q26 with $45 million in proforma cash, extending runway into 2027.”
Achieve positive Medicare coverage policy for EsoGuard to enable broader reimbursement and commercial adoption.
Stated in 2 of last 2 quarters. Management emphasizes Medicare coverage as a key pending milestone. No financial or revenue impact from Medicare coverage is reported yet, indicating the priority remains in progress with limited substantive delivery so far.
“We continue to advance multiple commercial priorities while awaiting a positive draft Medicare coverage policy for EsoGuard.”
“Securing Medicare coverage remains our most important pending milestone, and our confidence in a positive outcome has not wavered.”
Over the trailing year it converted 0.76x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, real (inflation-adjusted) rates, the US dollar, long-term interest rates, Fed net liquidity (low R² over the window).
13 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.